- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07912684
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial (Hematowellness)
This multicenter, prospective, pilot randomized controlled trial aims to evaluate the feasibility and preliminary efficacy of a 16-week structured exercise program (SEP) in patients with hematologic malignancies, including acute myeloid leukemia, lymphoma, and multiple myeloma.
A total of 75 patients will be randomized in a 1:1 ratio to either a supervised exercise intervention or a control group receiving usual care and general advice on physical activity.
The intervention consists of a personalized, hybrid exercise program combining supervised home- and gym-based training, aerobic and resistance exercises, balance and stretching activities, and behavioral counseling.
The primary objective is to assess the feasibility of the intervention in terms of adherence to the exercise program and patient satisfaction.
Secondary objectives include evaluating intervention-related adverse events, patient-reported burden, health-related quality of life, fatigue, physical fitness, anthropometric parameters, and physical activity levels.
Assessments will be conducted at baseline, approximately 8 weeks, 16 weeks (end of intervention), and 24 weeks after randomization.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Bari, Itália, 70126
- Ainda não está recrutando
- Irccs Oncologico Istituto Tumori Giovanni Paolo Ii - Bari - Uo Ematologia
-
Contato:
- Carla Minoia
- Número de telefone: +390805555905
- E-mail: carla.minoia1@gmail.com
-
Verona, Itália, 37134
- Ainda não está recrutando
- Aou Integrata Di Verona, Policlinico G.B. Rossi - Uoc Ematologia
-
Contato:
- Carlo Visco
- Número de telefone: +39045 8027488
- E-mail: carlo.visco@univr.it
-
-
Rm
-
Roma, Rm, Itália, 00133
- Recrutamento
- Fondazione PTV Policlinico Tor Vergata
-
Contato:
- Maria Christina Cox
- Número de telefone: +393382268017
- E-mail: chrisscox@gmail.com
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
**Inclusion Criteria:**
-
Patients aged between 18 and 75 years.
-
ECOG Performance Status ≤2.
-
Patients discharged after first-line intensive treatments (Category A), including:
- Acute myeloid leukemia (AML) in clinical remission following first-line intensive treatment (post-consolidation), within 30 days of hospital discharge, and not candidates for transplantation.
- Multiple myeloma in clinical remission following first-line treatment with autologous stem cell transplantation, within 30 days of hospital discharge.
- Lymphoma in clinical remission following first-line intensive treatment (e.g., CODOX-M/IVAC, HYPER-CVAD, DA-EPOCH, CHOP/DHAP, with or without autologous stem cell transplantation consolidation), within 30 days of hospital discharge.
-
Patients receiving or having received first-line treatment in an outpatient setting (Category B), including:
- Multiple myeloma in complete remission, having completed first-line treatment within the previous 30 days and undergoing maintenance therapy.
- Lymphoma patients undergoing first-line treatment with at least 12 weeks of therapy remaining.
-
Written informed consent provided.
**Exclusion Criteria:**
- Undergoing monotherapy with monoclonal antibodies.
- More than one line of systemic treatment.
- Estimated life expectancy of less than 6 months.
- Severe neurological illness.
- Lack of cardiology clearance or left ventricular ejection fraction below 50%.
- Unstable fractures or metastases inducing skeletal fragility, as determined by the treating hematologist, or recent femoral or vertebral fracture (within the previous 12 months).
- Serious active infection.
- Uncontrolled severe respiratory insufficiency or dependency on oxygen supplementation at rest or during exercise.
- Uncontrolled severe pain.
- Any other comorbidity contraindicating physical exercise.
- Any circumstances preventing adherence to study requirements or the ability to provide informed consent.
- Logistical barriers preventing adherence to the exercise program, as judged by the treating hematologist (e.g., distance from training locations, work commitments, or family circumstances).
- Regular engagement in physical activity according to current guidelines during the previous 6 months.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Structured Exercise Program (SEP)
Participants randomized to the intervention group will receive a 16-week personalized, supervised, hybrid structured exercise program (SEP), combining home- and gym-based training. The program includes aerobic, resistance, balance, and stretching exercises, a structured walking program, and behavioral counseling. Exercise sessions will be supervised by trained exercise professionals, either in person or remotely, according to the intervention phase. |
A 16-week structured and supervised exercise program tailored to the individual patient's clinical condition and physical abilities. The intervention includes aerobic exercise, resistance training, balance and flexibility exercises, walking activities, and behavioral counseling. Exercise sessions may be conducted in person or at home with remote supervision, according to the patient's needs and clinical status.
Outros nomes:
|
|
Sem intervenção: Control
Participants randomized to the control group will receive usual care and general information about the benefits of physical activity. They will not participate in the supervised structured exercise program during the study period. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Adherence to the Structured Exercise Program
Prazo: At 16 weeks (end of intervention)
|
Adherence will be assessed as the percentage of participants in the intervention group who attend at least 65% of the planned supervised exercise sessions. The intervention will be considered feasible if at least 70% of participants meet this adherence t |
At 16 weeks (end of intervention)
|
|
Patient Satisfaction With the Structured Exercise Program
Prazo: At 16 weeks (end of intervention)
|
Patient satisfaction will be assessed in the intervention group using the item "Overall, I am satisfied with the exercise program" from a study-specific satisfaction questionnaire. Responses are rated on a 4-point scale: "disagree", "somewhat disagree", "somewhat agree", and "agree". Satisfaction will be measured as the percentage of participants responding "somewhat agree" or "agree". The intervention will be considered feasible if at least 75% of participants meet this satisfaction criterion. |
At 16 weeks (end of intervention)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in Health-Related Quality of Life (EORTC QLQ-C30)
Prazo: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Health-related quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30). Changes in mean scores across all questionnaire scales will be compared between and within study groups. Scores are transformed to a 0-100 scale, with higher scores indicating better functioning or global health status on functional and global health scales, and greater symptom burden on symptom scales. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Change in Fatigue (FACIT-Fatigue)
Prazo: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Fatigue will be assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) questionnaire. Changes in mean fatigue scores will be compared between and within study groups at baseline, 8 weeks, and 16 weeks. Fatigue will also be assessed at 24 weeks for descriptive follow-up analyses. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Study Engagement Rate
Prazo: During the 18-month recruitment period.
|
The engagement rate will be calculated as the percentage of patients who agree to participate in the study among all patients invited to participate. Reasons for refusal will be documented to identify potential barriers to study participation. |
During the 18-month recruitment period.
|
|
Incidence of Intervention-Related Adverse Events
Prazo: Throughout the 16-week intervention period.
|
The number and severity of adverse events potentially related to the structured exercise program will be assessed in the intervention group. Adverse events will be monitored and recorded by exercise professionals and study personnel throughout the intervention period. Severity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. |
Throughout the 16-week intervention period.
|
|
Patient-Reported Burden of the Intervention (FACT-G Item GP5)
Prazo: At 8 weeks (T1) and 16 weeks (T2) after randomization.
|
Patient-Reported Burden of the Intervention (FACT-G Item GP5) |
At 8 weeks (T1) and 16 weeks (T2) after randomization.
|
|
Change in Physical Activity Levels (Godin-Shephard Questionnaire)
Prazo: Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
Changes in physical activity levels will be assessed using the Godin-Shephard Leisure-Time Physical Activity Questionnaire, which evaluates the frequency of mild, moderate, and vigorous physical activity performed during leisure time. Changes will be compared between and within study groups. |
Baseline (T0), 8 weeks (T1), 16 weeks (T2), and 24 weeks (T3) after randomization.
|
|
Non-Hematological Adverse Events
Prazo: Throughout the 16-week intervention period.
|
The prevalence of non-hematological adverse events of grade 3 or higher will be described and compared between the intervention and control groups. Adverse event severity will be classified according to CTCAE version 5.0. |
Throughout the 16-week intervention period.
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Doenças Vasculares
- Doenças cardiovasculares
- Neoplasias
- Doenças do sistema imunológico
- Neoplasias por Tipo Histológico
- Doenças Hematológicas
- Doenças Linfáticas
- Distúrbios Linfoproliferativos
- Distúrbios imunoproliferativos
- Leucemia Mieloide
- Neoplasias de Células Plasmáticas
- Distúrbios hemostáticos
- Paraproteinemias
- Distúrbios das Proteínas Sanguíneas
- Distúrbios hemorrágicos
- Leucemia
- Doenças hemic e linfáticas
- Leucemia Mieloide Aguda
- Linfoma
- Mieloma múltiplo
Outros números de identificação do estudo
- GIMEMA QoL-Hematowellness
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .